Clinical trials: Depressive; Behavioral Disorder
Depressive Disorder, Depression
Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
To compare the effect of OPC-34712 (brexpiprazole) to the effect of placebo (an inactive substance) as add on treatment to an assigned FDA approved antidepressant treatment (ADT) in patients with Major Depressive Disorder who…
- Conditions
- Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders
- Trial name
- Polaris (NCT01360632)
- Testing
- OPC-34712 + ADT
- Where
- 71 sites in United States, Canada and 5 more
- Volunteers
- 1,539 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depression
PRIME Care (PRecision Medicine In MEntal Health Care)
The focus of this application is on the impact of providing depressed Veterans and their providers with the results of pharmacogenetic (PGx) testing for psychotropic medications.
- Trial name
- PRIME Care (NCT03170362)
- Testing
- Pharmacogenetic Test
- Where
- 24 sites in United States
- Volunteers
- 1,944 people
- Sponsor
- VA Office of Research and Development
Schizophrenia, Depression
Quetiapine Extended Release Depression Symptoms
Aim of the study is to assess if the new compound Seroquel XR™ is non-inferior to Risperidone, considered as the reference drug for the treatment of depressive symptoms of schizophrenia.
- Trial name
- ExAttitude (NCT00640562)
- Testing
- Quetiapine Extended Release, Risperidone
- Where
- 21 sites in Italy
- Volunteers
- 216 people
- Sponsor
- AstraZeneca
Anxiety Disorder, Depressive Disorder
Feasibility of a Culturally Adapted Emotional-Behavioral Prevention Program for American Indian Children
American Indians (AI) are at greater risk for anxiety and depression early in life. This is concerning given the potential negative effects of these conditions across the lifespan (substance use, suicide).
- Trial name
- NCT05371665
- Testing
- Culturally Adapted Cognitive-Behavioral Prevention and Early Intervention (PEI) Program
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Montana State University
Depression, Alcoholism
Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism
We will study patients with a current major depressive episode, comorbid alcoholism and a history of a past suicide attempt. All subjects with alcohol dependence will be evaluated for risk of alcohol withdrawal prior to…
- Conditions
- Depression, Alcoholism, Suicidal Behavior
- Trial name
- NCT00449007
- Testing
- fluoxetine, bupropion
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- New York State Psychiatric Institute
Seasonal Affective Disorder, Depression
Cognitive Behavioral Therapy for the Treatment of Seasonal Affective Disorder (SAD)
This study will assess the effectiveness of cognitive behavioral therapy (CBT) in treating seasonal affective disorder (SAD), commonly called the "winter blues."
- Trial name
- NCT00076245
- Testing
- Light Therapy, Cognitive behavioral therapy (CBT)
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
Major Depressive Disorder, Healthy Controls
Effects of Treatment on Decision-making in Major Depression
In this trial, fifty participants with current major depressive disorder who are not receiving an antidepressant medication and fifty healthy controls will complete questionnaires and computerized tasks to assess their…
- Trial name
- NCT01916824
- Testing
- Any FDA Approved Antidepressant
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Emory University
Major Depressive Disorder
Frontal Hypoperfusion Effects on Antidepressant Outcomes in Late-Life Depression
The long-term goal of this line of research is to determine if decreased vascular reactivity and frontal hypoperfusion is associated with poor response antidepressants.
- Trial name
- NCT01896934
- Testing
- Sertraline
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Vanderbilt University
Major Depressive Disorder
Combination Deplin® and Antidepressant Therapy for a Major Depressive Episode (MDE)- a Retrospective Analysis
This is a retrospective chart review study to determine if Deplin® 7.5mg-15mg combined with an antidepressant is better than an antidepressant alone in adults with major depression.
- Trial name
- NCT01001559
- Testing
- L-methylfolate, Selective serotonin reuptake inhibitor (SSRI), Serotonin and norepinephrine reuptake inhibitor (SNRI)
- Where
- United States
- Volunteers
- 242 people
- Sponsor
- Pamlab, Inc.
Cigarette Smoking, Schizophrenia
Integrated Smoking Cessation Treatment for Smokers With Serious Mental Illness
The overall aim of this study is to test the effect of academic detailing (i.e. provider-level educational intervention focused on evidence-based smoking cessation treatment for those with psychiatric illness) and community…
- Conditions
- Cigarette Smoking, Schizophrenia, Bipolar Disorder, Depressive Disorder, Major
- Trial name
- NCT02845440
- Testing
- Academic Detailing, Community Health Worker, Treatment as Usual (TAU)
- Where
- United States
- Volunteers
- 1,165 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Study of Neural Responses Induced by Antidepressant Effects
The proposed work aims to examine the neural changes associated with fast-acting antidepressant treatments in order to develop imaging-based biomarkers of treatment response for depression.
- Trial name
- SONRISA (NCT02674529)
- Testing
- Escitalopram, Real-time Neurofeedback fMRI task pre- and post-RCT
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Marta Peciña, MD PhD
Depression
Effectiveness of Methylphenidate in Improving Cognition and Function in Older Adults With Depression
This study will evaluate the safety and effectiveness of methylphenidate in improving cognition and function in older adults with depression.
- Trial name
- NCT00602290
- Testing
- Citalopram, Methylphenidate (MPH)
- Where
- United States
- Volunteers
- 181 people
- Sponsor
- University of California, Los Angeles
Anhedonia, Major Depressive Disorder
Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD
To evaluate the efficacy of NBI-1065846 compared with placebo on improving symptoms of anhedonia in participants with major depressive disorder (MDD).
- Trial name
- TERPSIS (NCT05165394)
- Testing
- NBI-1065846
- Where
- 23 sites in United States, Puerto Rico
- Volunteers
- 93 people
- Sponsor
- Neurocrine Biosciences
Major Depressive Disorder, Treatment Resistant Depression
Open-Label Safety Study of AXS-05 in Subjects With Depression
An open-label, long-term, safety study of AXS-05 in patients with major depressive disorder (MDD), including treatment resistant depression.
- Conditions
- Major Depressive Disorder, Treatment Resistant Depression, Depression
- Trial name
- NCT04039022
- Testing
- AXS-05 (dextromethorphan and bupropion) oral tablets
- Where
- 51 sites in United States
- Volunteers
- 876 people
- Sponsor
- Axsome Therapeutics, Inc.
Depression
Reclaim Deep Brain Stimulation Clinical Study for Treatment-Resistant Depression
Medtronic, Inc. sponsored an investigational study of the Reclaim™ Deep Brain Stimulation (DBS) System in people that have treatment-resistant depression.
- Trial name
- NCT00837486
- Testing
- Reclaim™ DBS System
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- MedtronicNeuro
Major Depressive Disorder
Psilocybin-assisted CBT for Depression
The primary objectives of this clinical investigation are to (1) determine the acceptability and feasibility of joining psilocybin-assisted therapy with cognitive-behavioral therapy (PA-CBT) for patients with depression, (2)…
- Trial name
- NCT05227612
- Testing
- Psilocybin, Cognitive behavioral therapy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of California, Los Angeles
Major Depressive Disorder
Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs
The purpose of this study is to see if adding the study drug, ziprasidone, to an antidepressant medication helps improve symptoms of Major Depressive Disorder (MDD).
- Trial name
- NCT00633399
- Testing
- Ziprasidone
- Where
- 2 sites in United States
- Volunteers
- 458 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Magnetic Resonance Imaging Study of Geriatric Depression
The purpose of this study was to use Magnetic Resonance Images to further our understanding of predictors and markers of treatment response and non-response in geriatric depression.
- Trial name
- NCT00245557
- Testing
- Sertraline
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Depression
Ketamine Plus Lithium in Treatment-Resistant Depression
The purpose of this study is to test the antidepressant effect of ketamine when given repeatedly over a period of 1 week, as well as the use of Lithium as a relapse-prevention strategy for patients with treatment-resistant…
- Trial name
- NCT01880593
- Testing
- Lithium, Ketamine
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Depressive Episodes, Bipolar I Depression
A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).
This is a clinical trial to determine the long-term safety and tolerability of an investigational drug in people with Major Depressive Episode Associated with Bipolar I Disorder (Bipolar I Depression).
- Trial name
- NCT05227209
- Testing
- SEP-4199 CR
- Where
- 69 sites in United States, Bulgaria and 1 more
- Volunteers
- 64 people
- Sponsor
- Sumitomo Pharma America, Inc.